Acomhal Research Inc, -- a biotech spun out of the Virginia Tech Carilion Research Institute -- is structured around working on an innovative therapeutic drug to target chemoresistant cancer cells and prevent tumor recurrence in glioblastoma. With the firm's described mission is that of development of novel and effective therapeutic approaches targeting tumor recurrence and metastasis, the principals are developing new proprietary drugs more effectively to treat primary cancer tumors n a manner that result in less recurrence and fewer metastases, thereby improving patient outcomes. A particular compound being studied by Acomhal has the potential to target cancer stem cells, which are the seeds from which a number of different tumors are thought to grow.
